{"disease":{"id":"atrial-flutter","name":"Atrial flutter","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":6},"drugs":{"marketed":[{"drug_id":"flecainide","indication_name":"Paroxysmal Atrial Fibrillation/Flutter (PAF)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"ibutilide","indication_name":"Rapid conversion of atrial fibrillation or atrial flutter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Corvert","generic_name":"IBUTILIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"flecainide-acetate","indication_name":"Paroxysmal Atrial Fibrillation/Flutter (PAF)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLECAINIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"tikosyn","indication_name":"Conversion of Atrial Fibrillation/Flutter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tikosyn","generic_name":"Dofetilide","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"IKr potassium channel (rapid component of delayed rectifier potassium current)","drug_class":"Vaughan Williams Class III antiarrhythmic","quality_score":10,"revenue":null,"mechanism":"Blocks cardiac potassium channel IKr to prolong repolarization and delay arrhythmia recurrence."},{"drug_id":"flecainide","indication_name":"Paroxysmal atrial flutter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"dofetilide","indication_name":"Cardioversion of Atrial Flutter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tikosyn","generic_name":"DOFETILIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic [EPC]","quality_score":65,"revenue":null,"mechanism":"Tikosyn works by blocking the potassium channels in the heart, which helps to regulate the heart's rhythm."},{"drug_id":"verapamil-hydrochloride","indication_name":"Control of ventricular rate at rest in patients with chronic atrial flutter and/or atrial fibrillation (in association with digitalis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"verapamil-hydrochloride","indication_name":"Control of ventricular rate during stress in patients with chronic atrial flutter and/or atrial fibrillation (in association with digitalis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"non-interventional-study","indication_name":"Atrial Flutter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"landiolol","indication_name":"Atrial flutter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onoact","generic_name":"LANDIOLOL","company_name":"Aop Hlth Us","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"landiolol","quality_score":37,"revenue":null,"mechanism":"Onoact works by blocking the beta-1 adrenergic receptor, which helps to slow down abnormal heart rhythms."},{"drug_id":"ibutilide","indication_name":"Cardioversion of Atrial Flutter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Corvert","generic_name":"IBUTILIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":60,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":28,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03335800","title":"Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias","phase":"NA","overall_status":"COMPLETED","enrollment_count":419927,"lead_sponsor_name":"Apple Inc.","has_results":true},{"nct_id":"NCT04545437","title":"The Short and Long-term Cardiovascular Consequences of Critical Illness: The C3 Study","phase":"","overall_status":"UNKNOWN","enrollment_count":80000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT00412984","title":"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":20976,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT04126486","title":"A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":11931,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03129490","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":11000,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT04919902","title":"Prague Registry of Electric Cardioversion","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Institute for Clinical and Experimental Medicine","has_results":false},{"nct_id":"NCT05521451","title":"Clinical Cohort Study - TRUST","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT04512222","title":"EARLY-MYO-AF Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT05903313","title":"A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software","phase":"","overall_status":"UNKNOWN","enrollment_count":4306,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT05009225","title":"Clinical Decision Support for Atrial Fibrillation and Flutter","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT04738071","title":"International Multicenter Patent foRamen OVale & strokE (IMPROVE) Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":3730,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT03310125","title":"Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3209,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT03272620","title":"Atrial Fibrillation at the Viennese University Emergency Department","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT05838781","title":"DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation","phase":"NA","overall_status":"COMPLETED","enrollment_count":2112,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04456842","title":"Cardiovascular Registry of Atrial Fibrillation","phase":"","overall_status":"COMPLETED","enrollment_count":2016,"lead_sponsor_name":"Brazilian Clinical Research Institute","has_results":false},{"nct_id":"NCT04436978","title":"What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"St. Antonius Hospital","has_results":false},{"nct_id":"NCT03243604","title":"cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study","phase":"","overall_status":"COMPLETED","enrollment_count":1717,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT06486636","title":"Pericardiotomy in Cardiac Surgery","phase":"NA","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT05773170","title":"Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and Flutter","phase":"","overall_status":"COMPLETED","enrollment_count":1147,"lead_sponsor_name":"R-Pharm","has_results":false},{"nct_id":"NCT05468281","title":"RAFF5 Proposal: Improve the Quality and Safety of Patients Seen in the Emergency Department for Acute Atrial Fibrillation and Flutter","phase":"","overall_status":"COMPLETED","enrollment_count":1108,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":false},{"nct_id":"NCT03707873","title":"Effect of Targeted Education for Atrial Fibrillation Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":1040,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT04096781","title":"Engaging Patients to Help Achieve Increased Patient Choice and Engagement for AFib Stroke Prevention","phase":"NA","overall_status":"COMPLETED","enrollment_count":1001,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT05355948","title":"A Clinical Trial to Evaluate the Detection of Atrial Fibrillation for an One Day Versus More Than or Equal to Eight Days Using MEMO Patch PLUS in Individuals Aged ≥ 75 Years, or Those at High Risk of Stroke","phase":"NA","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07196176","title":"Electrophysiological Registry Duesseldorf","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT07239804","title":"Systematic Assessment of Treatment Effectiveness for Long-Term Management of Stable Atrial Tachycardia in Inpatient and Outpatient Environments","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Evangelical Hospital Düsseldorf","has_results":false},{"nct_id":"NCT03627143","title":"Decreasing Hospital Admissions From the ED for AAFF","phase":"NA","overall_status":"COMPLETED","enrollment_count":846,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":false},{"nct_id":"NCT06460831","title":"A Comparative Study Evaluating the Vein of MArshall Ethanol Infusion Ablation Using an Over-the-wire (OTW) Balloon Versus a microcatHeter in Patients With Atrial Fibrillation","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT03911986","title":"Risk-Based Screening for the Evaluation of Atrial Fibrillation Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":755,"lead_sponsor_name":"National University of Ireland, Galway, Ireland","has_results":false},{"nct_id":"NCT06519747","title":"DETECTion of PeriOperative Atrial Fibrillation After Noncardiac Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT06187155","title":"Impact of Education Level on Clinical Outcomes in Self-INR Managed Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":586,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT07447297","title":"Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation","phase":"NA","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT07109141","title":"Registry of Atrial Arrhythmia Ablation Procedures Using Pulsed Field Ablation in Poland","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Wroclaw Medical University","has_results":false},{"nct_id":"NCT04300270","title":"Validation of a Novel Smartphone-based Method for Heart Rhythm Monitoring in the Home Environment","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":480,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05509517","title":"A Clinical Trial of the Use of Remote Heart Rhythm Monitoring With a Smartphone After Cardiac Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":450,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT03231826","title":"Arrhythmias in Post-Myocardial Infarction Patients","phase":"","overall_status":"COMPLETED","enrollment_count":445,"lead_sponsor_name":"Tampere University","has_results":false},{"nct_id":"NCT05391893","title":"Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Corewell Health South","has_results":true},{"nct_id":"NCT03867266","title":"Typical Atrial Flutter, Ablation Index and Point by Point Ablation","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Ospedale San Francesco","has_results":false},{"nct_id":"NCT02793895","title":"Detection of Atrial Fibrillation After Cardiac Surgery","phase":"NA","overall_status":"TERMINATED","enrollment_count":336,"lead_sponsor_name":"Unity Health Toronto","has_results":false},{"nct_id":"NCT03376438","title":"Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia","phase":"","overall_status":"COMPLETED","enrollment_count":330,"lead_sponsor_name":"Edgar Jaeggi","has_results":false},{"nct_id":"NCT04141553","title":"Bolus vs IVP (Intravenous Push) Diltiazem for Atrial Fibrillation or Flutter","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Mercy Health Muskegon","has_results":false},{"nct_id":"NCT05920226","title":"Myocardial Fibrosis in Patients With Permanent Pacemakers","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Ryazan State Medical University","has_results":false},{"nct_id":"NCT07079813","title":"Clinical Study on the Efficiency of Rapid Arrhythmia Mapping Using EasyStars™ High Density Mapping Catheter Applications","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Shanghai MicroPort EP MedTech Co., Ltd.","has_results":false},{"nct_id":"NCT04472936","title":"Long-term outcomeS of cavotrIcuspid isthMus-dePendent fLuttEr Ablation: Single vs Double Catheter Procedure","phase":"NA","overall_status":"COMPLETED","enrollment_count":253,"lead_sponsor_name":"Centro Medico Teknon","has_results":false},{"nct_id":"NCT04593498","title":"Excessive Supraventricular Activity and Atrial Fibrillation","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03288766","title":"SHERLOCK 3CG™ Diamond Tip Confirmation System","phase":"","overall_status":"TERMINATED","enrollment_count":232,"lead_sponsor_name":"C. R. Bard","has_results":false},{"nct_id":"NCT03720639","title":"Confirm Rx™ Versus Reveal LINQ™ - Which is More Reliable in Data Transmission? A Randomized Clinical Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Sparrow Clinical Research Institute","has_results":false},{"nct_id":"NCT03153150","title":"Start or STop Anticoagulants Randomised Trial (SoSTART)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":203,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT06087497","title":"The Z Stitch Early Bed Rest Assessment Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Oregon Health and Science University","has_results":false},{"nct_id":"NCT03591627","title":"Left Atrial Thrombus on Transesophageal Echocardiography","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Medical University of Warsaw","has_results":false},{"nct_id":"NCT06452823","title":"Efficacy and Safety of Catheter Ablation of Atrial Fibrillation in Patients With Thyroid Hormone Stabilization","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"The Second Affiliated Hospital of Jiaxing University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}